Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

TRU-016 abstracts to be presented at ASH meeting

Emergent BioSolutions Inc. today announced the acceptance of four abstracts for presentation at the 52nd Annual Meeting of the American Society of Hematology to be held from December 4 to 7 in Orlando, Florida. The presentations include an oral presentation on the results of a Phase I dose escalation, monotherapy study of TRU-016 for patients with chronic lymphocytic leukemia.

10 Nov 2010

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

Researchers have further established that long-term use of statins is unlikely to substantially increase or decrease overall cancer risk, according to study results presented at the Ninth Annual AACR Frontiers in Cancer Prevention Research Conference, held Nov. 7-10, 2010, in Philadelphia.

10 Nov 2010

ARIAD reports $20.4 million net loss for third quarter 2010

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2010 and provided an update on corporate developments.

9 Nov 2010

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).

9 Nov 2010

Patients with germinal center-like structures face greater risk of developing non-Hodgkin's lymphoma

Biopsying the glands that produce saliva to test for germinal center-like formation when someone is diagnosed with primary Sjögren's Syndrome can predict later development of non-Hodgkin's lymphoma, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

9 Nov 2010

Children with JIA face increase risk of developing cancer

Children with juvenile idiopathic arthritis have a two to threefold increased risk of developing cancer compared to similarly-aged children without JIA, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta. The same study also reported no cases of cancer in children with JIA who were exposed to anti-TNF therapy.

9 Nov 2010

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited today announced that brentuximab vedotin (SGN-35) will be featured in two oral presentations at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 4-7, 2010 in Orlando, FL.

9 Nov 2010

SIMPONI injection improves inflammation, structural damage in RA patients

Magnetic resonance imaging (MRI) analyses from two Phase 3 clinical trials showed that once every four week subcutaneous injections of SIMPONI (golimumab) 50 mg plus methotrexate resulted in statistically significant improvements in markers of inflammation and structural damage in patients with active rheumatoid arthritis (RA) compared with placebo plus methotrexate.

9 Nov 2010

Research reveals EBV virus infected cell manipulates cancer-producing cells

A new discovery by UNC scientists describes how cells infected by the Epstein-Barr virus (EBV) produce small vesicles or sacs called exosomes, changing their cellular "cargo" of proteins and RNA. This altered exosome enters cells and can change the growth of recipient cells from benign to cancer-producing.

9 Nov 2010

People with SLE more likely to develop hematologic malignancies

People with systemic lupus erythematosus are 1.15 times as likely to develop cancer as the general population and more than 2.5 times as likely to develop hematologic malignancies, such as lymphoma and leukemia, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta.

8 Nov 2010

SGN-35 drug reduces tumor growth in Hodgkin's lymphoma

An experimental drug for Hodgkin's lymphoma, studied at the University of Alabama at Birmingham, showed beneficial effects in stopping tumor growth with moderate side-effects, according to findings published Thursday in the New England Journal of Medicine.

8 Nov 2010

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results and operational highlights for the quarter ended September 30, 2010.

4 Nov 2010

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that data from a phase I single-agent clinical trial of brentuximab vedotin (SGN-35) will be published in the November 4, 2010 issue of the New England Journal of Medicine.

4 Nov 2010

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced positive preliminary results of a Phase IIa study in inflammatory bowel disease (IBD) with its lead autoimmune compound vidofludimus, an oral inhibitor of interleukin-17 (IL-17) release.

4 Nov 2010

New findings show combinational therapy effective for patients with DLBCL lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults. If left untreated, it is fatal. The existing treatments have a cure rate that is slightly over 50 percent but destroy healthy cells along with the cancer cells.

4 Nov 2010

Low vitamin D levels linked to cancer progression and death in CLL patients

Researchers at Mayo Clinic have found a significant difference in cancer progression and death in chronic lymphocytic leukemia (CLL) patients who had sufficient vitamin D levels in their blood compared to those who didn't.

4 Nov 2010

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced that it has received a grant of $244,479 from the United States Government to help fund the Company's Phase I clinical trial of its lead cancer drug candidate Liposomal Grb-2. The amount of funds awarded was the maximum allocation allowed under the program.

4 Nov 2010

PIKAMAB awarded QTDP program grants to advance development of theragnostic products

PIKAMAB, a biopharmaceutical company specializing in stratified medicine, announced today that it has been awarded two grants by the U.S. Government under the QTDP program to advance the development and commercialization of two theragnostic products: ADCC Therasight and Lupus Therasight. PIKAMAB applied for two grants, both of which qualified and received the maximum grant amounts totaling approximately $488,959.

4 Nov 2010

New antibody with SGN-35 drug produces remission in Hodgkin lymphoma

An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38 percent of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in a phase I clinical trial, investigators report in the Nov. 4 issue of the New England Journal of Medicine.

4 Nov 2010

Immunomedics product candidates, technologies receive recognition from QTDP program

Immunomedics, Inc. a biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that all 12 applications from the Company were certified by the Internal Revenue Service of the Department of Treasury as qualified investments in accordance with the Qualifying Therapeutic Discovery Project (QTDP) program under section 48D of the Internal Revenue Code. As a result, the Company will receive an aggregate cash award of $2.9 million.

3 Nov 2010

Lymphoma News and Research

Further Reading

TRU-016 abstracts to be presented at ASH meeting

Long-term use of statins unlikely to substantially increase overall cancer risk: Study

ARIAD reports $20.4 million net loss for third quarter 2010

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Patients with germinal center-like structures face greater risk of developing non-Hodgkin's lymphoma

Children with JIA face increase risk of developing cancer

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

SIMPONI injection improves inflammation, structural damage in RA patients

Research reveals EBV virus infected cell manipulates cancer-producing cells

People with SLE more likely to develop hematologic malignancies

SGN-35 drug reduces tumor growth in Hodgkin's lymphoma

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

New England Journal of Medicine publishes brentuximab vedotin Phase I clinical trial data

4SC's vidofludimus Phase IIa study in IBD meets primary endpoint

New findings show combinational therapy effective for patients with DLBCL lymphoma

Low vitamin D levels linked to cancer progression and death in CLL patients

Bio-Path awarded $244,479 federal grant for Liposomal Grb-2 Phase I clinical trial

PIKAMAB awarded QTDP program grants to advance development of theragnostic products

New antibody with SGN-35 drug produces remission in Hodgkin lymphoma

Immunomedics product candidates, technologies receive recognition from QTDP program

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News